CME Group And CF Benchmarks Launch New BTC And ETH Reference Rates For Asia-Pacific

Key Points:

• CME Group, the world’s leading derivatives market, and CF Benchmarks, a leading provider of crypto benchmark indices announced plans to launch two new APAC-specific reference rates for bitcoin and ether on September 11.
• Reference Rates, namely CME CF Bitcoin Reference Rate APAC (BRRAP) and CME CF Ether-Dollar Reference Rate APAC (ETHUSD_AP).
• These two rates will be announced at 4pm Hong Kong/Singapore time.

CME Group and CF Benchmarks today announced plans to launch two new reference rates exclusively for Asia-Pacific for bitcoin and ether on September 11.

Reference Rates, namely CME CF Bitcoin Reference Rate APAC (BRRAP) and CME CF Ether-Dollar Reference Rate APAC (ETHUSD_AP). These two rates will provide a once-daily reference rate for the USD prices of the two digital assets, announced at 4pm Hong Kong/Singapore time.

These new reference rates are designed to meet the evolving needs of global participants in the growing digital asset space. These APAC reference rates will allow market participants to more accurately and accurately hedge cryptocurrency prices at a time that is better suited to their portfolios.

According to CME Group, 37% of total crypto volume at CME Group was traded outside of US hours, with 11% of trades coming from the APAC region.

CME Group enables clients to trade futures, options, cash and OTC markets, optimize portfolios and analyze data – empowering market participants worldwide to manage Manage risks and seize opportunities effectively.

In addition, CF Benchmarks is a leading provider of cryptocurrency benchmarks, authorized and regulated by the UK FCA under EU BMR. Consisting of market data from six constituent exchanges, its benchmark indices are made available through transparent governance and public methods, to monitor, price and address risk in products. electronic financial products and services.

DISCLAIMER: The Information on this website is provided as general market commentary and does not constitute investment advice. We encourage you to do your own research before investing.